Finanzen von Hyperfine Inc (HYPR)HYPRHyperfine Inc

Hyperfine, Inc. (HYPR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DEVICE, accounting for 83.4% of total sales, equivalent to $3.26M. Another important revenue stream is SERVICE. Understanding this composition is critical for investors evaluating how HYPR navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Hyperfine, Inc. maintains a gross margin of 50.72%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -216.93%, while the net margin is -238.17%. These profitability ratios, combined with a Return on Equity (ROE) of -96.97%, provide a clear picture of how effectively HYPR converts its operational activities into shareholder value.

In the context of the broader market, HYPR competes directly with industry leaders such as SKIN and ECOR. With a market capitalization of $88.36M, it holds a significant position in the sector. When comparing efficiency, HYPR's gross margin of 50.72% stands against SKIN's 68.42% and ECOR's 86.53%. Such benchmarking helps identify whether Hyperfine, Inc. is trading at a premium or discount relative to its financial performance.

Hyperfine's revenue for Q1 2026 was $3.90 million, with a gross margin of 51%, but the company continues to report significant net losses, with a net income of -9,298,000 USD in Q2 2026.